Can-Fite Biopharma Ltd ADR (CANF) Stock Price, Quote & News

Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic c...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 3 924 1114

Fax: 972 3 924 9378

Website: www.canfite.com

Address:

26 Ben Gurion Street, Ramat Gan, Israel

supplySHOCK Jun. 4 at 10:28 AM

$BNZI $HTOO $NAAS $CANF cause

1 · Reply

GeeJoon Jun. 3 at 11:39 PM

$CANF i have strong feeling they would releaae psoriasis P3 interim data this week or next, before BIO international convention on 22 June, piclidenoson has already completed a P3 in 2022 so stay positive, 100m market cap

0 · Reply

Bigsaltyone Jun. 2 at 6:50 PM

$CANF

0 · Reply

DARKP00L Jun. 2 at 11:57 AM

$CANF 07:02 on Jun. 02 2026 Can-Fite Highlights Pancreatic Cancer Drug Progress #tradeideas

1 · Reply

Agguie Jun. 2 at 11:47 AM

$CANF this just never really wants to move after the big rug pull on the halt.

0 · Reply

focafoca99 Jun. 2 at 11:29 AM

$CANF stated positive Phase 2a pancreatic cancer data for Namodenoson, highlighting RAS signaling inhibition.

0 · Reply

GeeJoon Jun. 2 at 9:30 AM

$CANF Piclidenoson drug candidate: Can-Fite is currently enrolling patients in a pivotal Phase III clinical study for the treatment of psoriasis. In this study, patients receive Piclidenoson orally, administered twice daily. The primary efficacy endpoints of the trial are PASI 75 (Psoriasis Area and Severity Index) and Physician’s Global Assessment (PGA), consistent with regulatory guidance for late-stage psoriasis studies. Based on the Company’s current assumptions, interim analysis data is expected to be released in the second quarter of 2026. The Company also completed the development of a Phase II study protocol for the rare genetic disease Lowe Syndrome and plans to submit it to regulatory authorities in Italy and EMA during Q1 2026.

0 · Reply

GeeJoon Jun. 2 at 9:06 AM

$CANF meet all end points in psoriasis p3 interim would be also a great support to piclidenoson being evaluated in dogs osteoarthritis

0 · Reply

MarketMasterMind Jun. 2 at 1:46 AM

$CANF loading back up here tomorrow. Chart is primed just taking longer than expected… 🤑Ⓜ️

0 · Reply

GeeJoon Jun. 1 at 11:50 PM

$CANF 28 days remaining for psoriasis p3 interim data

0 · Reply

Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson's RAS Signaling Inhibition Mechanism

Mon, 18 May 2026 07:00:00 -0400 - 17 days ago

Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson's Potential in the Multi-Billion Dollar Canine Osteoarthritis Market

2026-05-13T13:49:05.000Z - 22 days ago

Can-Fite BioPharma upgraded to Buy from Hold at D. Boral Capital

Wed, 13 May 2026 07:00:00 -0400 - 22 days ago

Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy

2026-05-12T10:49:37.000Z - 23 days ago

Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright

Thu, 30 Apr 2026 08:31:00 -0400 - 5 weeks ago

Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months

Mar 31, 2026, 8:00 AM EDT - 2 months ago

Can-Fite BioPharma Registration statement: Registration filing

2026-03-31T10:16:55.000Z - 2 months ago

Can-Fite BioPharma files to sell 3.29M ordinary shares for holders

2026-03-30T22:03:00.000Z - 2 months ago

Can-Fite BioPharma (CANF) Advances Osteoarthritis Treatment for Dogs

2026-03-30T11:37:18.000Z - 2 months ago

Can-Fite BioPharma completes enrollment in Piclidenoson study

Mon, 30 Mar 2026 07:20:00 -0400 - 2 months ago

Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026

Mar 26, 2026, 9:30 AM EDT - 2 months ago

Can-Fite BioPharma Annual report: Q4 2025

Mar 26, 2026, 9:30 AM EDT - 2 months ago

Can-Fite BioPharma Quarterly report: Q4 2025

Thu, 26 Mar 2026 09:27:00 -0400 - 2 months ago

Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient

2026-03-17T13:28:03.000Z - 2 months ago

Can-Fite BioPharma (CANF) Secures Key Patent for Obesity Treatment

2026-03-17T11:50:14.000Z - 2 months ago

Can-Fite BioPharma announces Israeli patent allowance for namodenoson

Tue, 17 Mar 2026 07:47:00 -0400 - 2 months ago

Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance

2026-03-04T16:50:16.000Z - 3 months ago

Can-Fite's Namodenoson Hits Phase 2a Goal; Raises $4M Via Warrants

Wed, 04 Mar 2026 10:07:28 -0500 - 3 months ago

Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study

2026-03-04T12:34:33.000Z - 3 months ago

Can-Fite BioPharma (CANF) Achieves Positive Results in Pancreatic Cancer Study

2026-03-04T12:09:03.000Z - 3 months ago

Can-Fite BioPharma says namodenoson meets primary endpoint in Phase 2a study

Wed, 04 Mar 2026 07:00:00 -0500 - 3 months ago

Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study

2026-02-17T12:36:34.000Z - 3 months ago

Can-Fite BioPharma (CANF) Unveils Promising Obesity Study Results

2026-02-17T12:15:35.000Z - 3 months ago

Can-Fite BioPharma announces publication of anti-obesity effect of namodenoson

2026-02-09T12:30:05.000Z - 4 months ago

Can-Fite (CANF) Gains Canadian Patent for Anti-Obesity Drug Namodenoson

2026-02-09T12:15:27.000Z - 4 months ago

Can-Fite BioPharma receives Canadian patent allowance for namodenoson

2026-02-05T12:33:49.000Z - 4 months ago

Can-Fite BioPharma (CANF) Treatment Aids Successful Liver Transplant

2026-02-05T12:17:59.000Z - 4 months ago

Can-Fite announces patient with liver cirrhosis treated with Namodenoson

2026-01-20T12:37:35.000Z - 4 months ago

Can-Fite BioPharma (CANF) Completes Patient Enrollment in Pancreatic Cancer Trial

2026-01-20T12:10:21.000Z - 4 months ago

Can-Fite completes patient enrollment in Phase 2a study of Namodenoson

2025-12-24T15:50:08.000Z - 5 months ago

Can-Fite BioPharma downgraded to Hold from Buy at D. Boral Capital

2025-12-23T22:55:20.000Z - 5 months ago

Can-Fite BioPharma (CANF) Announces 1-for-3,000 Reverse Stock Split

2025-12-23T22:25:23.000Z - 5 months ago

Can-Fite BioPharma (CANF) Announces Significant Reverse Split

2025-12-23T21:50:11.000Z - 5 months ago

Can-Fite BioPharma announces 1-for-3,000 reverse split, ratio change

Tue, 23 Dec 2025 16:46:00 -0500 - 5 months ago

Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change

2025-12-17T13:30:15.000Z - 6 months ago

CANF: D. Boral Capital Lowers Price Target But Maintains Buy Rating | CANF Stock News

2025-12-16T15:29:50.000Z - 6 months ago

CANF: Can-Fite BioPharma Advances Clinical Trials and Strengthens Financial Position

2025-12-16T14:25:37.000Z - 6 months ago

Can-Fite BioPharma provides clinical, financial update

Tue, 16 Dec 2025 09:19:00 -0500 - 6 months ago

Can-Fite Provides Update on Clinical and Financial Status

2025-11-24T12:30:24.000Z - 6 months ago

Can-Fite BioPharma (CANF) to Engage in Strategic Collaborations at BioFIT 2025

2025-11-24T12:15:09.000Z - 6 months ago

Can-Fite BioPharma to participate in BioFIT 2025

2025-11-20T12:42:31.000Z - 7 months ago

Can-Fite BioPharma (CANF) Secures Patent Approval in Brazil for Erectile Dysfunction Treatment

2025-11-20T12:05:46.000Z - 7 months ago

Can-Fite BioPharma receives Notice of Allowance from Brazil for patent on CF602

Thu, 20 Nov 2025 07:00:00 -0500 - 7 months ago

Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil

2025-11-18T20:00:37.000Z - 7 months ago

CANF: Analyst Jason Kolbert Maintains Buy Rating and Price Target | CANF Stock News

2025-11-18T14:19:26.000Z - 7 months ago

Why Is Can-Fite BioPharma Stock (CANF) Up Today?

2025-11-18T12:30:20.000Z - 7 months ago

Can-Fite BioPharma's (CANF) Namodenoson Shows Promising Long-Term Survival

2025-11-18T12:16:46.000Z - 7 months ago

Can-Fite announces 9-year survival with complete cure with Namodenoson

2025-11-04T12:01:46.000Z - 7 months ago

CANF: HC Wainwright Initiates Buy Rating with $2.50 Price Target | CANF Stock News

2025-11-04T11:16:11.000Z - 7 months ago

Can-Fite BioPharma assumed with a Buy at H.C. Wainwright

2025-09-16T12:32:06.000Z - 9 months ago

CANF: Analyst Jason Kolbert Maintains Buy Rating and $11 PT | CANF Stock News

2025-09-15T11:05:28.000Z - 9 months ago

Can-Fite BioPharma announces new findings for Namodenoson

CANF

2025-08-28T12:55:30.000Z - 10 months ago

Can-Fite BioPharma reports 1H EPS 0c vs. 0c last year

CANF

Aug 28, 2025, 8:47 AM EDT - 10 months ago

Can-Fite Reports H1 2025 Financial Results and Clinical Update

Aug 27, 2025, 6:00 PM EDT - 10 months ago

Can-Fite BioPharma Quarterly report: Q2 2025

Jul 30, 2025, 7:04 AM EDT - 11 months ago

Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone

Jul 28, 2025, 12:24 PM EDT - 11 months ago

Can-Fite Announces Up To $15.0 Million Public Offering

Jul 28, 2025, 7:00 AM EDT - 11 months ago

Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia

Jul 25, 2025, 8:00 AM EDT - 11 months ago

Can-Fite BioPharma Registration statement: Registration Filing

Jul 23, 2025, 8:00 AM EDT - 11 months ago

Can-Fite BioPharma Registration statement: Registration Filing

Apr 17, 2025, 8:55 AM EDT - 1 year ago

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Apr 14, 2025, 2:28 PM EDT - 1 year ago

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Can-Fite BioPharma Annual report: Q4 2024

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Can-Fite BioPharma Quarterly report: Q4 2024

Mar 20, 2025, 9:45 AM EDT - 1 year ago

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Mar 19, 2025, 9:00 AM EDT - 1 year ago

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Mar 3, 2025, 6:00 AM EST - 1 year ago

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Feb 10, 2025, 7:10 AM EST - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25

Feb 5, 2025, 7:00 AM EST - 1 year ago

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

Dec 30, 2024, 7:00 AM EST - 1 year ago

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson

Nov 23, 2024, 7:01 PM EST - 1 year ago

Can-Fite BioPharma Transcript: C-level Sitdown

Nov 22, 2024, 9:00 AM EST - 1 year ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

SXTP

Nov 11, 2024, 7:00 AM EST - 1 year ago

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Nov 4, 2024, 7:08 AM EST - 1 year ago

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Oct 29, 2024, 4:15 PM EDT - 1 year ago

Can-Fite BioPharma Transcript: Investor Update

Oct 18, 2024, 9:06 AM EDT - 1 year ago

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

Oct 9, 2024, 7:00 AM EDT - 1 year ago

FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

Aug 30, 2024, 8:00 AM EDT - 1 year ago

Can-Fite BioPharma Registration statement: Registration Filing

Aug 29, 2024, 8:15 AM EDT - 1 year ago

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

Aug 29, 2024, 7:00 AM EDT - 1 year ago

Can-Fite BioPharma Earnings release: Q2 2024

Aug 10, 2024, 7:00 PM EDT - 1 year ago

Can-Fite BioPharma Transcript: C-level Sitdown

Aug 9, 2024, 9:00 AM EDT - 1 year ago

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

OSTX

Aug 8, 2024, 7:01 PM EDT - 1 year ago

Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

Aug 8, 2024, 4:15 PM EDT - 1 year ago

Can-Fite BioPharma Transcript: Investor Update

Jul 29, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Provides Namodenoson Patent Update

Jul 17, 2024, 7:00 AM EDT - 2 years ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8

Jul 11, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer

Jun 28, 2024, 7:00 AM EDT - 2 years ago

Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner Vetbiolix

Jun 24, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver

Jun 10, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Jun 6, 2024, 4:15 PM EDT - 2 years ago

Can-Fite BioPharma Transcript: Investor Update

Jun 5, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

May 29, 2024, 7:00 AM EDT - 2 years ago

Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases

May 27, 2024, 7:00 AM EDT - 2 years ago

Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024

May 23, 2024, 7:00 AM EDT - 2 years ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6

May 13, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study

May 11, 2024, 7:00 PM EDT - 2 years ago

Can-Fite BioPharma Transcript: C-level Sitdown

May 10, 2024, 9:00 AM EDT - 2 years ago

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NTRB

May 9, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

May 6, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

Apr 25, 2024, 7:00 AM EDT - 2 years ago

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

Apr 15, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Apr 3, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV

supplySHOCK Jun. 4 at 10:28 AM

$BNZI $HTOO $NAAS $CANF cause

1 · Reply

GeeJoon Jun. 3 at 11:39 PM

0 · Reply

Bigsaltyone Jun. 2 at 6:50 PM

$CANF

0 · Reply

DARKP00L Jun. 2 at 11:57 AM

$CANF 07:02 on Jun. 02 2026 Can-Fite Highlights Pancreatic Cancer Drug Progress #tradeideas

1 · Reply

Agguie Jun. 2 at 11:47 AM

$CANF this just never really wants to move after the big rug pull on the halt.

0 · Reply

focafoca99 Jun. 2 at 11:29 AM

$CANF stated positive Phase 2a pancreatic cancer data for Namodenoson, highlighting RAS signaling inhibition.

0 · Reply

GeeJoon Jun. 2 at 9:30 AM

0 · Reply

GeeJoon Jun. 2 at 9:06 AM

$CANF meet all end points in psoriasis p3 interim would be also a great support to piclidenoson being evaluated in dogs osteoarthritis

0 · Reply

MarketMasterMind Jun. 2 at 1:46 AM

$CANF loading back up here tomorrow. Chart is primed just taking longer than expected… 🤑Ⓜ️

0 · Reply

GeeJoon Jun. 1 at 11:50 PM

$CANF 28 days remaining for psoriasis p3 interim data

0 · Reply

GeeJoon May. 30 at 5:05 AM

$CANF buckle up, psoriasis P3 interim data will be out anytime soon, and meeting with leading oncology companies in June during BIO International Convention... - Q2: psoriasis p3 interim data - Q3: dogs osteoarthritis p2 data - Q3: MASH p2b data - Q3: pancreatic cancer p2a data - Q4: liver cancer HCC CPB7 p3 interim data

0 · Reply

GeeJoon May. 27 at 1:15 PM

$CANF

0 · Reply

GeeJoon May. 20 at 2:33 PM

$CANF psoriasis P3 interim data in Q2 and pancreatic cancer p2a data in June during Bio International Conventio, let's if more inst buying

0 · Reply

Kingcrab33333 May. 20 at 2:07 AM

$CANF

0 · Reply

MarketMasterMind May. 18 at 1:48 PM

$GEDC | $CANF 🤑Ⓜ️

0 · Reply

OpenOutcrier May. 18 at 12:38 PM

$CANF (+7.7% pre) Can-Fite and Vetbiolix Gain Peer-Reviewed Validation for Piclidenoson in Canine Osteoarthritis https://ooc.bz/l/102666

0 · Reply

GeeJoon May. 18 at 11:26 AM

$CANF https://ir.canfite.com/news-events/press-releases/detail/1112/scientific-publication-of-can-fite-and-vetbiolix-validates

0 · Reply

GeeJoon May. 15 at 9:21 AM

$CANF Q2 has gone half, psoriasis pivot p3 data will be released soon!

0 · Reply

nicholalala May. 14 at 4:30 PM

$CANF Since I won on QUCY today and was taking stock of winners and losers, I just wanted to highlight the risks here. Last time this ran (to $13), management decided to pull the rug and sell shares at $4.09 I believe). BEWARE of this stock. Make your winnings and get out immediately. I lost my winnings from RXT here.

0 · Reply

MarketMasterMind May. 14 at 11:27 AM

$CANF | $GDC Ⓜ️

0 · Reply

GeeJoon May. 13 at 10:33 PM

$CANF 7m market cap, 2m float, entered into confidentiality agreements with several pharmaceutical companies to advance into pancreatic cancer p2b study evaluating namodenoson in combination with immunotherapy, will meet leading oncology companies in June during BIO International Convention... - Q2: psoriasis p3 interim data - Q3: dogs osteoarthritis p2 data - Q3: MASH p2b data - Q3: pancreatic cancer p2a data - Q4: liver cancer HCC CPB7 p3 interim data

0 · Reply

MarketMasterMind May. 13 at 7:53 PM

$CANF 🤫Ⓜ️

0 · Reply

Market Cap	2.04M
Revenue (ttm)	410,000.00
Net Income (ttm)	-9.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,397.56%
Debt to Equity Ratio	0.00

Volume	7,700
Avg Vol	609,120
Day's Range	N/A - N/A
Shares Out	655,000.00
Stochastic %K	12%
Beta	1.12
Analysts	Strong Sell
Price Target	$5.50